BELL & LINDSAY, INC.

Lobbying for DEMERX, INC · Clinical stage drug development company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Florida · House · Senate · $10,000.00 income · posted Jan 20, 2026

Lobbying activity 1

Health Issues

advocacy and education around the company's value proposition to advance medicines to break the cycle of alcohol and drug dependence.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.